Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and in Additional Clinical Targets
April 24, 2017 07:15 ET
|
Akari Therapeutics, Plc
-Interim Phase 2 PNH data demonstrate positive response with Coversin™-Phase 3 PNH program expected to commence in 4Q2017-Data from preclinical aHUS model demonstrates positive results-New preclinical...
Akari Therapeutics Announces R&D Day on April 24, 2017
March 17, 2017 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, March 17, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that it will hold a Research...
Akari Therapeutics Expands Clinical and Regulatory Teams with Industry Veterans
January 04, 2017 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, has expanded its clinical and regulatory teams....
Akari Therapeutics Announces Corporate Update with New Positive Clinical Data and a New Pipeline of Tick Derived and Engineered Proteins
December 05, 2016 07:00 ET
|
Akari Therapeutics, Plc
-Phase Ib cohorts demonstrate dose effect and additional support for once daily dosing--PAS-Coversin pre-clinical data supports once weekly dosing--Phase II PNH patients identified with data expected...
Akari Therapeutics to Attend Upcoming Investor Conferences In November
November 11, 2016 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief...
Akari Therapeutics to Present at Upcoming Investor Conferences on September 27 and 28 in New York City
September 16, 2016 12:18 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Sept. 16, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced that Dr. Gur Roshwalb, Chief...
Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Paroxysmal Nocturnal Hemoglobinuria
September 12, 2016 07:15 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that the U.S. Food and...
Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency to Conduct Phase 2 Trial in Paroxysmal Nocturnal Hemoglobinuria
July 13, 2016 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, July 13, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today the approval by the UK...
Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Paroxysmal Nocturnal Hemoglobinuria
July 12, 2016 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, July 12, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the European Medicines...
Akari Therapeutics Plc and XL-protein GmbH Sign License Agreement to Develop a Long Acting Version of Coversin Using PASylation® Technology
April 14, 2016 07:30 ET
|
Akari Therapeutics Plc
NEW YORK, LONDON, and FREISING, Germany, April 14, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, and XL-protein, a...